Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)
Launched by KU LEUVEN · Jul 30, 2013
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how nerve activity in the intestines may differ between people with Irritable Bowel Syndrome (IBS) and healthy individuals. Researchers will take small tissue samples, called biopsies, from the rectum of both IBS patients and healthy volunteers. They will then use these samples to study nerve activity and the presence of certain molecules that may affect how the gut works. The goal is to develop a new method to observe live nerve behavior in the intestines and learn more about the role of the nervous system in IBS.
To participate in this trial, you need to be either an IBS patient or a healthy person. The study is currently recruiting participants aged 18 to 75. If you join, you can expect to provide a biopsy, which is a quick procedure. The research team will analyze these samples to explore how different factors, including diet and inflammation, may influence nerve activity in the gut. This study is unique because it aims to provide insights that could lead to better understanding and treatment options for IBS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • IBS patients (based on ROME III Criteria)
- • Healthy subjects
- Exclusion Criteria:
- • - All subjects with not IBS related complaints
About Ku Leuven
KU Leuven, a prestigious research university located in Belgium, is renowned for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, KU Leuven integrates cutting-edge research with clinical practice, facilitating the development of new therapeutic strategies and medical technologies. The institution's robust infrastructure and expertise in various fields, including biotechnology, pharmacology, and public health, position it as a leader in conducting high-quality clinical research that adheres to rigorous ethical standards and regulatory requirements. Through its clinical trials, KU Leuven aims to contribute significantly to the global biomedical landscape and enhance health outcomes for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, Vlaams Brabant, Belgium
Patients applied
Trial Officials
Guy Boeckxstaens, MD
Principal Investigator
Catholic University Leuven and Universitary Hospitals Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials